PMID: 11900497Mar 20, 2002Paper

Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy

Annals of Internal Medicine
Louis D MayDavid E Rubin

Abstract

Pioglitazone is an oral hypoglycemic agent in the thiazolidinedione class. Only one case of hepatotoxicity related to this agent has previously been reported. To report the clinical course of a patient with hepatitis after therapy with pioglitazone. Case report. A community hospital. A 49-year-old diabetic man taking pioglitazone, 30 mg/d. Discontinuation of pioglitazone therapy. Serum aminotransferase and bilirubin levels, standard blood tests for causes of hepatitis and cirrhosis other than drug toxicity, and liver biopsy. After 6 months of pioglitazone therapy, significant hepatic dysfunction developed. Blood tests excluded viral, metabolic, and autoimmune disorders. Liver biopsy showed mixed hepatocellular-cholestatic injury compatible with drug toxicity. After treatment with pioglitazone was discontinued, liver enzyme values returned to normal. Patients receiving pioglitazone may develop serious liver injury and should be observed for evidence of hepatitis.

Citations

Jan 7, 2003·Pharmacoepidemiology and Drug Safety
Feb 7, 2004·Current Diabetes Reports·Emre Seli, Antoni J Duleba
Apr 10, 2013·Journal of Ethnopharmacology·Luo-sheng WanJiachun Chen
Dec 25, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Shoichiro ShishidoMichio Sata
Aug 2, 2003·The New England Journal of Medicine·William M Lee
Feb 11, 2005·Current Opinion in Gastroenterology·Jay H Lefkowitch
Feb 11, 2005·Current Opinion in Gastroenterology·Michael Trauner, James L Boyer
Jul 8, 2005·Journal of Clinical Gastroenterology·Stacy B MeneesRichard H Moseley
Dec 14, 2004·Southern Medical Journal·Lisa L Willett, Eric S Albright
Oct 17, 2006·Drugs·Emma D Deeks, Lesley J Scott
Jul 19, 2011·Therapeutic Advances in Gastroenterology·Lisa B Van Wagner, Mary E Rinella
Aug 22, 2006·Expert Review of Cardiovascular Therapy·Andreas PfütznerThomas Forst
Mar 1, 2006·Expert Opinion on Pharmacotherapy·Andreas Pfützner, Thomas Forst
Feb 25, 2009·Expert Opinion on Drug Safety·C V RizosE N Liberopoulos
Mar 4, 2011·Expert Opinion on Drug Safety·Keith G Tolman
Jul 7, 2007·Critical Reviews in Toxicology·T WangH M Mehendale
Oct 31, 2003·Expert Opinion on Drug Safety·William L Isley
Dec 9, 2015·Molecular Pharmaceutics·Floriane MontanariGerhard F Ecker
Apr 10, 2013·Asian Pacific Journal of Tropical Biomedicine·G Rajiv Gandhi, P Sasikumar
Nov 7, 2007·Endocrinology and Metabolism Clinics of North America·Mouen Khashab, Naga Chalasani
Feb 7, 2009·International Journal of Clinical Practice·J Philippe, D Raccah
Oct 4, 2011·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Douglas M FrederickPeter J Harvison
Oct 26, 2010·Journal of Ethnopharmacology·Xiao-ke ZhengXin Zhang
Feb 4, 2012·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Yun-Tao LiuYan-Jun Yang
Mar 15, 2013·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Arumugam Sathya, Perumal Siddhuraju
Mar 19, 2013·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Yuntao LiuYanjun Yang
Apr 10, 2003·Mayo Clinic Proceedings·Farhad ZangenehAnanda Basu
Sep 23, 2016·Evidence-based Complementary and Alternative Medicine : ECAM·Xiang-Zhou Li, Sheng Zhang
Aug 20, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Matthew G BurbankAndré Guillouzo
Jul 22, 2004·The Annals of Pharmacotherapy·Todd R MarcySteve M Blevins
Feb 1, 2017·Journal of Applied Toxicology : JAT·Rika HirashimaRyoichi Fujiwara
Jan 16, 2003·The Diabetes Educator·R Keith Campbell, John White
Jan 1, 2010·Clinical Medicine Insights. Endocrinology and Diabetes·Cyrus V Desouza, Vijay Shivaswamy
Jun 18, 2004·Current Medical Research and Opinion·Charles G Gegick, Michael D Altheimer
Jan 24, 2008·Environmental and Molecular Mutagenesis·Abdulkerim BedirMuhlise Alvur
Jun 7, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Hai-Xue KuangYong-Gang Xia
Jun 3, 2005·The American Journal of Gastroenterology·Naga ChalasaniStephen D Hall
Jul 23, 2009·Pharmacoepidemiology and Drug Safety·James S FloydSidney M Wolfe
Nov 5, 2005·Alimentary Pharmacology & Therapeutics·H ReynaertJ Henrion

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Hepatitis

Autoimmune hepatitis formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed. Discover the latest research on autoimmune hepatitis here.